FindTrial
Sign In

To explore the role of IL-6/JAK2 signaling in predicting colorectal cancer recurrence and its targeted therapy

To explore the role of IL-6/JAK2 signaling in predicting colorectal cancer recurrence and its targeted therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021957
Enrollment
Unknown
Registered
2019-03-17
Start date
2019-03-18
Completion date
Unknown
Last updated
2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Gold Standard:pathology
Index test:Determination&#32
of&#32
IL-6&#32
concentration&#32
by&#32
ELISA

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 20-80 years old; 2. Pre-operative pathological diagnosis of patients with colorectal cancer; 3. The patient underwent radical resection of colorectal cancer; 4. Colorectal cancer stage II, III, IV.

Exclusion criteria

Exclusion criteria: 1. Received neoadjuvant chemotherapy before surgery 2. With other types of digestive tract tumors

Design outcomes

Primary

MeasureTime frame
IL-6;—

Secondary

MeasureTime frame
CEA;JAK2;STAT3;p-JAK2;p-STAT3;—

Countries

China

Contacts

Public ContactXiong Yong

Shanghai Sixth People's Hospital

dongyuan_pwk@163.com+86 18930174031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026